Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology is attractive because MICVO has shown differentiated anti-tumor activity in a heavily pretreated 2L+ R/M HNSCC population, with a 36% confirmed objective response rate, 94% disease control rate, rapid responses, and a median progression-free survival of 6.2 months. The breadth of activity across HPV-positive and HPV-unrelated disease, plus responses after prior EGFR inhibitor and taxane exposure, supports the view that EDB+FN is a tractable ADC target and that MICVO could be positioned ahead of other late-stage options. Importantly, the dose-capping strategy improved the benefit-risk profile with lower treatment-related discontinuations at 14.3% and no treatment-related deaths, while the company’s upcoming 1H27 overall survival update offers a key catalyst if the early 79% 12-month survival probability is sustained.

Pyxis Oncology is a high-risk, pre-commercial oncology company with no revenue and a 2Q26 net loss of $0.40 per diluted share, worse than the $0.33 consensus loss, underscoring continued dependence on external capital. Its investment case hinges almost entirely on MICVO, but the drug still faces material clinical, regulatory, manufacturing, and commercial risk, and the reported 25% confirmed ORR in just 1/4 post-EGFRi patients is too limited to validate efficacy. Although cash and short-term investments were $33M and a July private placement added about $50M in gross proceeds, the company only expects funding into 2Q27, leaving dilution and development failure as central concerns.